Navigation Links
Yongye Biotechnology International, Inc. Appoints New Independent Auditor
Date:7/10/2008

BEIJING, July 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. ("Yongye" or the "Company") (OTC Bulletin Board: YGYB), a leading distributor of plant and animal nutrients headquartered in Beijing, PRC, announced today it has engaged MSPC Certified Public Accountants and Advisors, P.C. as the Company's independent auditor.

The Company has engaged MSPC Certified Public Accountants and Advisors, P.C. ("MSPC") to serve as the Company's independent auditor effective immediately. MSPC was founded in 1944 and provides traditional accounting services to a wide range of companies, from emerging entrepreneurial ventures to large, publicly held entities. MSPC is an active member in Moore Stephens North America and Moore Stephens International Limited, a network of leading, independently owned and operated accounting and consulting firms. MSPC enjoys wide representation in all metropolitan areas in the United States as well as worldwide. MSPC is regarded as one of the world's top twenty accounting and consulting networks with more than 316 independently owned and operated member firms. There are 539 offices in 93 countries throughout the world including Hong Kong and China. It has 15,404 principals and staff.

About Yongye Biotechnology, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the domestic distribution and sales of fulvic acid based nutritional compounds for plants and animals. The Company's patent pending process and proprietary formulas allow it to create products which increase the yields in crop production and improve livestock health. The Company sells its products to distributors and farmers located in ten provinces across China including: Xinjiang, Hebei, Inner Mongolia, Gansu, Hubei, Shandong, Anhui, Jiangsu, Yunan, and Guangdong.

FORWARD-LOOKING STATEMENTS

Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Larry Gilmore

Vice President of Corporate Strategy

Tel: +86-10-8232-8866 x8880

Fax: +86-10-8231-1797

Email: larry.gilmore@gmail.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
3. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
4. N.C. Biotechnology Center Launches Industrial Fellowship Program
5. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
6. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
7. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
8. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
9. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
10. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
11. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):